98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.drugpo.2024.104421 | DOI Listing |
JDS Commun
September 2025
Geno Breeding and AI Association, 2317 Hamar, Norway.
It is of interest to examine whether methane (CH) emission is genetically the same trait in young bulls and lactating dairy cows. The aim was therefore to estimate the genetic correlation between CH emissions for Norwegian Red young bulls and lactating cows. Measures of CH from GreenFeed (GF) were available from Geno's test station for young bulls and from GF units installed across 14 commercial dairy herds.
View Article and Find Full Text PDFCancer Discov
September 2025
Moffitt Cancer Center, Tampa, FL, United States.
There is growing interest in understanding the mechanisms underlying differences in cancer incidence among species (comparative oncology). The naked mole-rat (NMR) is often referenced as "cancer-resistant" and prior studies focused on identifying mechanisms explaining this. However, efforts to assess this in vivo have been limited.
View Article and Find Full Text PDFJ Alzheimers Dis Rep
September 2025
Epidemiology, IQVIA, Frankfurt am Main, Germany.
Background: Despite the availability of these therapies, maintaining long-term adherence remains a significant challenge.
Objective: This retrospective cohort study aimed to investigate 12-month and 5-year persistence with antidementia drug therapy in Germany and to examine the association between demographic and clinical variables and the risk of therapy discontinuation.
Methods: Patients aged 60 years or older from the IQVIA Longitudinal Prescription Database who received an initial prescription for antidementia therapy between 2016 and 2023 (index date) were included.
Patient
September 2025
Department of Public Health, University of Southern Denmark, Campusvej 55, 5230, Odense, Denmark.
Background: Patient and public involvement (PPI) is crucial for aligning research with public needs, reducing research waste, and enhancing the relevance and quality of evidence. Evaluating PPI is necessary to ensure its effectiveness. However, despite its recognised importance, researchers have reported a lack of robust tools for evaluating PPI systematically.
View Article and Find Full Text PDFAdv Ther
September 2025
Tolley Limited, Derbyshire, UK.
Introduction: Relative dose intensity (RDI) and dose delay factor (DDF) are important variables in cost-effectiveness analyses of oncology drugs that impact incremental cost-effectiveness ratios (ICERs). However, there is little published evidence on how RDI and DDF affect ICERs and how the calculation and application of these measures vary across health technology appraisals (HTAs). To understand this further, we analyzed National Institute for Health and Care Excellence (NICE) HTAs.
View Article and Find Full Text PDF